Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. IFNA6 - Wikipedia
IFNA6 - Wikipedia
From Wikipedia, the free encyclopedia
Protein-coding gene in the species Homo sapiens
IFNA6
Identifiers
AliasesIFNA6, IFN-alphaK, interferon alpha 6
External IDsOMIM: 147566; MGI: 2667155; HomoloGene: 105727; GeneCards: IFNA6; OMA:IFNA6 - orthologs
Gene location (Human)
Chromosome 9 (human)
Chr.Chromosome 9 (human)[1]
Chromosome 9 (human)
Genomic location for IFNA6
Genomic location for IFNA6
Band9p21.3Start21,349,835 bp[1]
End21,351,378 bp[1]
Gene location (Mouse)
Chromosome 4 (mouse)
Chr.Chromosome 4 (mouse)[2]
Chromosome 4 (mouse)
Genomic location for IFNA6
Genomic location for IFNA6
Band4 C4|4 42.02 cMStart88,561,878 bp[2]
End88,562,696 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • putamen

  • caudate nucleus

  • Brodmann area 9

  • amygdala

  • substantia nigra

  • hippocampus proper

  • occipital lobe

  • primary visual cortex

  • nucleus accumbens

  • hypothalamus
Top expressed in
  • embryo

  • embryo
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • cytokine activity
  • type I interferon receptor binding
  • cytokine receptor binding
Cellular component
  • extracellular region
  • extracellular space
  • cellular component
Biological process
  • natural killer cell activation involved in immune response
  • B cell differentiation
  • defense response
  • B cell proliferation
  • blood coagulation
  • positive regulation of peptidyl-serine phosphorylation of STAT protein
  • humoral immune response
  • adaptive immune response
  • defense response to virus
  • type I interferon signaling pathway
  • response to exogenous dsRNA
  • T cell activation involved in immune response
  • cytokine-mediated signaling pathway
  • innate immune response
  • regulation of signaling receptor activity
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

3443

230396

Ensembl

ENSG00000120235

ENSMUSG00000063376

UniProt

P05013

Q80SU4

RefSeq (mRNA)

NM_021002

NM_177347

RefSeq (protein)

NP_066282

NP_796321

Location (UCSC)Chr 9: 21.35 – 21.35 MbChr 4: 88.56 – 88.56 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interferon alpha-6 is a protein that in humans is encoded by the IFNA6 gene.[5][6]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000120235 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000063376 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Olopade OI, Bohlander SK, Pomykala H, Maltepe E, Van Melle E, Le Beau MM, Diaz MO (Dec 1992). "Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia". Genomics. 14 (2): 437–43. doi:10.1016/S0888-7543(05)80238-1. PMID 1385305.
  6. ^ "Entrez Gene: IFNA6 interferon, alpha 6".

Further reading

[edit]
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
  • Zhang Z, Henzel WJ (2005). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Sci. 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC 2286551. PMID 15340161.
  • Hardy MP, Owczarek CM, Jermiin LS, et al. (2005). "Characterization of the type I interferon locus and identification of novel genes". Genomics. 84 (2): 331–45. doi:10.1016/j.ygeno.2004.03.003. PMID 15233997.
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
  • Nyman TA, Tölö H, Parkkinen J, Kalkkinen N (1998). "Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes". Biochem. J. 329. ( Pt 2) (2): 295–302. doi:10.1042/bj3290295. PMC 1219044. PMID 9425112.
  • Tiefenbrun N, Melamed D, Levy N, et al. (1996). "Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest". Mol. Cell. Biol. 16 (7): 3934–44. doi:10.1128/MCB.16.7.3934. PMC 231390. PMID 8668211.
  • Henco K, Brosius J, Fujisawa A, et al. (1985). "Structural relationship of human interferon alpha genes and pseudogenes". J. Mol. Biol. 185 (2): 227–60. doi:10.1016/0022-2836(85)90401-2. PMID 4057246.
  • v
  • t
  • e
Cytokine receptor modulators
Chemokine
  • See here instead.
CSF
Erythropoietin
  • Agonists: ARA-290
  • Asialo erythropoietin
  • Carbamylated erythropoietin
  • CNTO-530
  • Darbepoetin alfa
  • Epoetin alfa
  • Epoetin beta
  • Epoetin delta
  • Epoetin epsilon
  • Epoetin gamma
  • Epoetin kappa
  • Epoetin omega
  • Epoetin theta
  • Epoetin zeta
  • Erythropoietin (EPO)
  • Erythropoietin-Fc
  • Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
  • Peginesatide
  • Pegol sihematide (EPO-018B)
G-CSF (CSF3)
  • Agonists: Filgrastim
  • Granulocyte colony-stimulating factor
  • Lenograstim
  • Leridistim
  • Lipegfilgrastim
  • Nartograstim
  • Pegfilgrastim
  • Pegnartograstim
GM-CSF (CSF2)
  • Agonists: Ecogramostim
  • Granulocyte macrophage colony-stimulating factor
  • Milodistim
  • Molgramostim
  • Regramostim
  • Sargramostim
  • Antibodies: Mavrilimumab
  • Namilumab
  • Otilimab
M-CSF (CSF1)
  • Agonists: Cilmostim
  • Interleukin-34
  • Lanimostim
  • Macrophage colony-stimulating factor
  • Mirimostim
  • Kinase inhibitors: Agerafenib
SCF (c-Kit)
  • See here instead.
Thrombopoietin
  • Agonists: Eltrombopag
  • Pegacaristim
  • Promegapoietin
  • Romiplostim
  • Avatrombopag
  • Lusutrombopag
  • Thrombopoietin (THPO, MGDF)
Interferon
IFNAR (α/β, I)
  • Agonists: Albinterferon
  • Interferon alpha (interferon alfa, IFN-α)
  • Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
  • Interferon alfa 2a
  • Interferon alfa 2b
  • Interferon alfa n1
  • Interferon alfacon-1
  • Interferon alpha-n3
  • Interferon beta (IFN-β) (IFNB1, IFNB3)
  • Interferon beta 1a
  • Interferon beta 1b
  • Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
  • Interferon omega (IFN-ω, IFNW1)
  • Peginterferon alfa-2a
  • Peginterferon alfa-2b
  • Antibodies: Anifrolumab
  • Faralimomab
  • MEDI-545
  • Rontalizumab
  • Sifalimumab
  • Decoy receptors: Bifarcept
IFNGR (γ, II)
  • Agonists: Interferon gamma (IFN-γ)
  • Interferon gamma 1b
  • Antibodies: Emapalumab
  • Fontolizumab
IFNLR (λ, III)
  • See IL-28R (IFNLR) here instead.
Interleukin
  • See here instead.
TGFβ
  • See here instead.
TNF
  • See here instead.
Others
JAK
(inhibitors)
JAK1
  • Abrocitinib
  • Baricitinib
  • Deuruxolitinib
  • Filgotinib
  • Momelotinib
  • Oclacitinib
  • Peficitinib
  • Ruxolitinib
  • Tofacitinib (tasocitinib)
  • Upadacitinib
JAK2
  • Atiprimod
  • AZD-1480
  • Baricitinib
  • CHZ868
  • Cucurbitacin I (elatericin B, JSI-124)
  • CYT387
  • Deuruxolitinib
  • Lestaurtinib
  • NSC-7908
  • NSC-33994
  • Pacritinib
  • Peficitinib
  • Ruxolitinib
  • SD-1008
  • Tofacitinib (tasocitinib)
JAK3
  • Cercosporamide
  • Decernotinib (VX-509)
  • Peficitinib
  • Ritlecitinib
  • TCS-21311
  • Tofacitinib (tasocitinib)
  • WHI-P 154
  • ZM-39923
  • ZM-449829
TYK2
  • Deucravacitinib
Others
  • Additional cytokines: Cardiotrophin 1 (CT-1)
  • FMS-like tyrosine kinase 3 ligand (FLT3L)
  • Leukemia/leukocyte inhibitory factor (LIF)
  • Oncostatin M (OSM)
  • Thymic stromal lymphopoietin (TSLP)
  • Additional cytokine receptor modulators: Emfilermin
  • Lestaurtinib
  • Midostaurin
  • Quizartinib
  • Sorafenib
  • Sunitinib


Stub icon

This article on a gene on human chromosome 9 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=IFNA6&oldid=1328170519"
Categories:
  • Genes on human chromosome 9
  • Human chromosome 9 gene stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • CS1: long volume value
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id